Limited efficacy of ICB has previously been linked to immunosuppressive tumor-associated neutrophils20,21; therefore, we reasoned that the altered tumor immune microenvironment (TIME) of Mt-Nd5 mutant tumors could allow for differential sensitivity to ICB, even in an aggressive model of poorly immunogenic melanoma such as B78-D14. The gene discussed is MT-ND5; the disease is melanoma.